OncoMatch/Clinical Trials/NCT06662006
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
Is NCT06662006 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies nal-IRI,5-fu,LV, benmelstobart, anlotinib for advanced metastatic pancreatic cancer.
Treatment: nal-IRI,5-fu,LV, benmelstobart, anlotinib — This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be assigned to liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT. The total sample size for this study is expected to be 56 subjects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced metastatic pancreatic cancer; Imaging suggests distant measurable lesions
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: first-line therapy — advanced/metastatic
Failure of first-line therapy
Cannot have received: fluorouracil
no use of fluorouracil ... in the first-line therapy
Cannot have received: irinotecan
no use of ... irinotecan ... in the first-line therapy
Cannot have received: liposomal irinotecan
no use of ... liposomal irinotecan drugs in the first-line therapy
Cannot have received: second-line or more anti-tumor therapy
Have received second-line or more anti-tumor therapy in the past
Lab requirements
Blood counts
Neutrophil count ≥ 1.5×10^9/L; Hemoglobin ≥ 10 g/dL; Platelet count ≥ 100×10^9/L
Kidney function
Creatinine clearance ≥ 60ml/min
Liver function
Total bilirubin ≤ 1.5× ULN; AST and ALT <1.5× ULN
Neutrophil count ≥ 1.5×10^9/L; Hemoglobin ≥ 10 g/dL; Platelet count ≥ 100×10^9/L; Total bilirubin ≤ 1.5× ULN; AST and ALT <1.5× ULN; Creatinine clearance ≥ 60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify